Showing results (21-30 of 41) with videos related to

Sort By:
Pageof 5
Molecular Endocrinology (Baltimore, Md.)|January 21, 2006
Suppression of androgen receptor signaling in prostate cancer cells by an inhibitory receptor variantLisa M Butler, Margaret M Centenera, Petra J Neufing, et al.
Scientific Reports|October 20, 2019
Evaluation of Small Molecule Drug Uptake in Patient-Derived Prostate Cancer Explants by Mass SpectrometryShadrack M Mutuku, Paul J Trim, Bala K Prabhala, et al.
JCO Precision Oncology|July 29, 2024
Circulating Lipid Profiles Associated With Resistance to Androgen Deprivation Therapy in Localized Prostate CancerHui-Ming Lin, Xiaoyu Yang, Margaret M Centenera, et al.
British Journal of Cancer|September 6, 2023
Targeting hyaluronan-mediated motility receptor (HMMR) enhances response to androgen receptor signalling inhibitors in prostate cancerJosephine A Hinneh, Joanna L Gillis, Chui Yan Mah, et al.
Nuclear Medicine and Biology|December 14, 2020
Synthesis and fluorine-18 radiolabeling of a phospholipid as a PET imaging agent for prostate cancerKim H Kwan, Ingrid J G Burvenich, Margaret M Centenera, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 11, 2012
Evidence for efficacy of new Hsp90 inhibitors revealed by ex vivo culture of human prostate tumorsMargaret M Centenera, Joanna L Gillis, Adrienne R Hanson, et al.
Molecular Cancer Research : MCR|July 17, 2020
Fatty Acid Oxidation Is an Adaptive Survival Pathway Induced in Prostate Tumors by HSP90 InhibitionZeyad D Nassar, Chui Yan Mah, Margaret M Centenera, et al.
The Prostate|January 10, 2018
Effect of FAK inhibitor VS-6063 (defactinib) on docetaxel efficacy in prostate cancerHui-Ming Lin, Brian Y Lee, Lesley Castillo, et al.
Cancer Research|July 30, 2009
Androgen receptor inhibits estrogen receptor-alpha activity and is prognostic in breast cancerAmelia A Peters, Grant Buchanan, Carmela Ricciardelli, et al.
Prostate Cancer and Prostatic Diseases|March 22, 2021
Aberrations in circulating ceramide levels are associated with poor clinical outcomes across localised and metastatic prostate cancerHui-Ming Lin, Kevin Huynh, Manish Kohli, et al.
Pageof 5